
About INCOG BioPharma Services
INCOG BioPharma Services is a Healthcare company based in United States founded in 2020 by Cory Lewis and Tedd Green. Injectable drug products are manufactured by this biopharma CDMO. INCOG BioPharma Services has raised $86.63 million across 5 funding rounds. Its chief executive, as recorded, is Cory Lewis. INCOG BioPharma Services offers products and services including Drug Development Services, Manufacturing Services, and Analytical and Quality Control. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Its legal entity is INCOG BioPharma Services, Inc. Its competitors include Exela Pharma, Summit Biosciences and ApiJect; 2 of its 3 listed competitors have raised funding.
Company details
INCOG BioPharma Services was founded in 2020 in the United States as a contract development and manufacturing organization. Emphasis is placed on the production of injectable drug products within the biopharmaceutical sector. Services encompass drug product manufacturing for clients, with operations based domestically. The company was co-founded by Cory Lewis, serving as CEO, and Tedd Green, serving as COO, supporting pharmaceutical development needs.
- Headquarters United States
- Founders Cory Lewis, Tedd Green
- SectorsHealthcare
- Website incogbiopharma.com
- Social LinkedIn
- Legal Name Incog Biopharma Services, Inc.
- Total Equity Funding$86.63M (USD)
in 5 rounds
- Latest Funding Round$42.86M (USD), Series C
May 2024
Products & Services of INCOG BioPharma Services
INCOG BioPharma Services offers a comprehensive portfolio of products and services, including Drug Development Services, Manufacturing Services, and Analytical and Quality Control.
Assists in developing injectable drug products for market acceleration
Manufactures injectable drugs using advanced facilities and quality controls
Provides testing for drug safety and compliance in pharmaceutical processes
Funding Insights of INCOG BioPharma Services
INCOG BioPharma Services has successfully raised a total of $86.63M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $42.86 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $86.63M
- Total Rounds 5
- Last Round Series C β $42.86M
- First Round $28.77M
(Sep 2020)
All 5 funding rounds of INCOG BioPharma Services with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $42.86M | Series C | β | β | β |
| Apr 2022 | Debt – Conventional | β | β | β | |
| Apr 2022 | $15M | Series B | β | β | β |
| Sep 2020 | $28.77M | Series B | β | β | β |
| Sep 2020 | Debt – Conventional | β | β | β |
People of INCOG BioPharma Services
2 people are tracked at INCOG BioPharma Services (2 in leadership).
| Name | Role | Group |
|---|---|---|
Cory Lewis | Co-Founder & CEO | Leadership |
Tedd Green | Co-Founder & COO | Leadership |
Complete people profiles for INCOG BioPharma Services
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of INCOG BioPharma Services
3 dated milestones of INCOG BioPharma Services across 4 years, from founding to its latest funding, stage changes and deals.
- Founded INCOG BioPharma Services is founded.
- Funding First funding round of $28.8M.
- Funding Latest funding round, Series C, of $42.9M.
Competitors of INCOG BioPharma Services
INCOG BioPharma Services has 3 listed competitors in our database, 2 of them funded. They include Exela Pharma, Summit Biosciences and ApiJect.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| exelapharma.com | 2005 | Lenoir, United States | $7.09M | 247 | Sterile injectable pharmaceuticals are manufactured alongside CDMO services. | |
| summitbiosciences.com | 2008 | Lexington, United States | Nasal spray drug products are developed, manufactured, and commercialized. | |||
| apiject.com | 2015 | Stamford, United States | $111M | Medicine injectors are manufactured by ApiJect for medical applications. |
Detailed competitors of INCOG BioPharma Services
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of INCOG BioPharma Services
The website of INCOG BioPharma Services (incogbiopharma.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▼ 10.2% vs previous month
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as INCOG BioPharma Services (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Incog Biopharma Services
Complete news archive for INCOG BioPharma Services
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about INCOG BioPharma Services
INCOG BioPharma Services was founded in 2020.
INCOG BioPharma Services is headquartered in United States.
Cory Lewis is the CEO of INCOG BioPharma Services, as recorded in our data. They have also founded this company.
INCOG BioPharma Services is a funded company, having raised a total of $86.63M across 5 funding rounds to date. The company's 1st funding round was a Series B of $28.77M, raised on Sep 2020.
INCOG BioPharma Services was founded in 2020 in the United States as a contract development and manufacturing organization. Emphasis is placed on the production of injectable drug products within the biopharmaceutical sector. Services encompass drug product manufacturing for clients, with operations based domestically. The company was co-founded by Cory Lewis, serving as CEO, and Tedd Green, serving as COO, supporting pharmaceutical development needs.
INCOG BioPharma Services's top competitors include Exela Pharma, Summit Biosciences and ApiJect.
INCOG BioPharma Services offers Drug Development Services, Manufacturing Services, and Analytical and Quality Control.
INCOG BioPharma Services operates through Incog Biopharma Services, Inc..
